Development of novel GI-centric prostaglandin E(2) receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases.
- DOI
- 10.1016/j.bmcl.2025.130093
- Published
- 2025 Apr 15
- Container
- Bioorganic & medicinal chemistry letters
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bmcl.2025.130093,
title = {Development of novel GI-centric prostaglandin E(2) receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases.},
author = {Kantham S and Yu H and Cantelli CR and Chen G and Ma C and Chan JJ and Yang H and Tsai K and Lassueur K and Vallance BA and Jacobson K and Young RN},
year = {2025},
journal = {Bioorganic \& medicinal chemistry letters},
doi = {10.1016/j.bmcl.2025.130093},
url = {https://doi.org/10.1016/j.bmcl.2025.130093}
}RIS
TY - JOUR TI - Development of novel GI-centric prostaglandin E(2) receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases. AU - Kantham S AU - Yu H AU - Cantelli CR AU - Chen G AU - Ma C AU - Chan JJ AU - Yang H AU - Tsai K AU - Lassueur K AU - Vallance BA AU - Jacobson K AU - Young RN PY - 2025 JO - Bioorganic & medicinal chemistry letters DO - 10.1016/j.bmcl.2025.130093 UR - https://doi.org/10.1016/j.bmcl.2025.130093 ER -
APA
S, K., H, Y., CR, C., G, C., C, M., JJ, C., H, Y., K, T., K, L., BA, V., K, J., & RN, Y. (2025). Development of novel GI-centric prostaglandin E(2) receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases.. Bioorganic & medicinal chemistry letters. https://doi.org/10.1016/j.bmcl.2025.130093
Source records
- pubmed · retrieved 2026-09-25T14:39:19.671Z